Design
depressive, anxiety
SECONDARY, DISORDERS
This study was designed as a single-centre, assessor-blinded, randomized, parallel-group superiority trial with a target sample of 104 patients with depressive and/or anxiety disorders with a primary time point of 21 weeks and a secondary follow-up period of 43 weeks. The participants were recruited from December 2013 to March 2018. The detailed study protocol, including the rationale of the comparison group, a detailed description of study settings, and the procedures, has been previously published (Ito et al., 